-+ 0.00%
-+ 0.00%
-+ 0.00%

According to Zhitong Finance App, Sinqi Pharmaceutical (300573.SZ) announced that the SQ-24071 eye drops developed by the company recently completed the first “multi-center, randomized, double-blind, placebo-controlled phase I clinical trial evaluating the safety, tolerability, and pharmacokinetics of SQ-24071 eye drops in myopic children and young participants” and officially entered phase I clinical trials.

Zhitongcaijing·11/16/2026 07:57:08
Listen to the news
According to Zhitong Finance App, Sinqi Pharmaceutical (300573.SZ) announced that the SQ-24071 eye drops developed by the company recently completed the first “multi-center, randomized, double-blind, placebo-controlled phase I clinical trial evaluating the safety, tolerability, and pharmacokinetics of SQ-24071 eye drops in myopic children and young participants” and officially entered phase I clinical trials.